Sacubitril/Valsartan for CKD5 Stage Dialysis Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 330 participants.

Also called NCT05243199

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 330 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05243199
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05243199. Randomized; no masking; primary purpose treatment. Start 2020-08-01 (actual); primary completion 2023-03-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Sacubitril/Valsartan for CKD5 Stage Dialysis Patients
Condition
CKD5 Stage Dialysis
Condition
Heart Failure
Intervention (Drug)
Sacubitril/Valsartan
Intervention (Drug)
Irbesartan
Lead sponsor
Ruijin Hospital (class: other)

Record details

Record id
cardio:ct-nct05243199
Content hash
4d05d61a26db011652db2f3a68ca1761aa9b8ebbc7987318acaa39ffbfdaf0cf